Clinical trial
Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA)…
NCT01760291 · Boston Scientific Corporation, Industry · Completed
Key facts
| NCT number | NCT01760291 |
|---|---|
| Title | Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology |
| Official title | Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology |
| Acronym | CAP2 |
| Lead sponsor | Boston Scientific Corporation, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Device |
| Interventions | WATCHMAN LAA Closure Technology |
| Enrollment | 576 |
| Start date | Sep 1, 2012 |
| Primary completion | Apr 1, 2019 |
| Completion | Apr 1, 2019 |
| First posted | Jan 4, 2013 |
| Last update posted | Mar 29, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: